Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Cour Pharmaceuticals Development has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
Cour Pharmaceuticals Development's investors include Sanofi, Lumira Ventures, Alpha Wave Global, Pfizer Venture Investments, Bristol-Myers Squibb.
Cour Pharmaceuticals Development is headquartered in Skokie, United States.
Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Cour Pharmaceuticals Development is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cour Pharmaceuticals Development — Funding & Investors." VCBacked, June 18, 2026, https://www.vcbacked.co/company/cour-pharmaceuticals-development. Accessed July 31, 2026.
VCBacked. (2026). Cour Pharmaceuticals Development — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/cour-pharmaceuticals-development
{{cite web |title=Cour Pharmaceuticals Development — Funding & Investors |url=https://www.vcbacked.co/company/cour-pharmaceuticals-development |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated